TY - JOUR
T1 - Catalysis of regioselective reduction of NAD(+) by ruthenium(II) arene complexes under biologically relevant conditions
AU - Yan, YK
AU - Melchart, M
AU - Habtemariam, A
AU - Peacock, Anna
AU - Sadler, PJ
PY - 2006/6/1
Y1 - 2006/6/1
N2 - Ruthenium(II) arene anticancer complexes [(eta(6)-arene)Ru(en)Cl]PF6 (arene is hexamethylbenzene, p-cymene, indan; en is ethylenediamine) can catalyse regioselective reduction of NAD(+) by formate in water to form 1,4-NADH, at pD 7.2, 37 degrees C, and in the presence of air. The catalytic activity is markedly dependent on the arene, with the hexamethylbenzene (hmb) complex showing the highest activity. For [(eta(6)-hmb)Ru(en)Cl]PF6, the rate of reaction is independent of NAD(+) concentration and shows saturation kinetics with respect to formate concentration. A K (m) value of 58 mM and a turnover frequency at saturation of 1.46 h(-1) were observed. Removal of chloride and performing the reaction under argon led to higher reaction rates. Lung cancer cells (A549) were found to be remarkably tolerant to formate even at millimolar concentrations. The possibility of using ruthenium arene complexes coadministered with formate as catalytic drugs is discussed.
AB - Ruthenium(II) arene anticancer complexes [(eta(6)-arene)Ru(en)Cl]PF6 (arene is hexamethylbenzene, p-cymene, indan; en is ethylenediamine) can catalyse regioselective reduction of NAD(+) by formate in water to form 1,4-NADH, at pD 7.2, 37 degrees C, and in the presence of air. The catalytic activity is markedly dependent on the arene, with the hexamethylbenzene (hmb) complex showing the highest activity. For [(eta(6)-hmb)Ru(en)Cl]PF6, the rate of reaction is independent of NAD(+) concentration and shows saturation kinetics with respect to formate concentration. A K (m) value of 58 mM and a turnover frequency at saturation of 1.46 h(-1) were observed. Removal of chloride and performing the reaction under argon led to higher reaction rates. Lung cancer cells (A549) were found to be remarkably tolerant to formate even at millimolar concentrations. The possibility of using ruthenium arene complexes coadministered with formate as catalytic drugs is discussed.
KW - catalysis
KW - NAD
KW - arene
KW - ruthenium
KW - organometallic complex
U2 - 10.1007/s00775-006-0098-5
DO - 10.1007/s00775-006-0098-5
M3 - Article
C2 - 16604356
SN - 1432-1327
VL - 11
SP - 483
EP - 488
JO - Journal of Biological Inorganic Chemistry
JF - Journal of Biological Inorganic Chemistry
IS - 4
ER -
